Comparative Pharmacology
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
MECLIZINE HYDROCHLORIDE vs PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
None Documented
None Documented
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic